Felix Lichtenegger: Highly effective Steering Committee Meeting with leading US lung cancer specialists

Felix Lichtenegger, Vice President Clinical Development at CatalYm GmbH, reposted a post by CatalYm GmbH on LinkedIn, adding the following:

“Highly effective Steering Committee Meeting this morning with a fantastic group of US lung cancer specialists. Thanks a lot to Roy Herbst, Jhanelle Gray, Mariam Alexander, Aakash Desai, MD, MPH, Jorge Nieva, Rajwanth Veluswamy and Wallace Akerley for the very interactive discussions and great contributions. I am very much looking forward to the further cooperation with you to bring this new exciting treatment option to NSCLC patients!”

Quoting CatalYm GmbH’s post:

“Catalym at World Conference on Lung Cancer 2024 (WCLC24) in San Diego!

In the early hours today we conducted our US Lung cancer program Steering Committee session with Roy Herbst and other leading US lung cancer specialists, with presentations by Felix Lichtenegger, our VP Clinical Development and Eugen Leo, our CMO. Data updates on the latest efficacy and safety data of our GDF15 blocking antibody visugromab were provided and our future GDFATHER lung cancer program in 1L and 2L NSCLC was reviewed. The trials are expected to start in early 2025 and will evaluate the efficacy and safety of visugromab in non-squamous NSCLC. And – more good news on visugromab data will come soon! Stay tuned!”

Source: Felix Lichtenegger/LinkedIn and CatalYm GmbH/LinkedIn